[开放获取]    中国儿童特应性皮炎预防、治疗与管理实践共识（2026版）

doi:10.35541/cjd.20250462

中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (6): 487-504.doi: 10.35541/cjd.20250462

• 指南与共识·特应性皮炎 • 上一篇下一篇

[开放获取] 中国儿童特应性皮炎预防、治疗与管理实践共识（2026版）

中华医学会皮肤性病学分会儿童皮肤病学组中华医学会儿科学分会皮肤病学组中国康复医学会皮肤病康复专业委员会儿童学组中国康复医学会皮肤病康复专业委员会特应性皮炎学组中国医师协会皮肤科医师分会儿童皮肤病学组中国医师协会儿科学分会皮肤病学组

中华医学会皮肤性病学分会儿童皮肤病学组中华医学会儿科学分会皮肤病学组中国康复医学会皮肤病康复专业委员会儿童学组中国康复医学会皮肤病康复专业委员会特应性皮炎学组中国医师协会皮肤科医师分会儿童皮肤病学组中国医师协会儿科学分会皮肤病学组

收稿日期:2025-08-27 修回日期:2026-04-18 发布日期:2026-06-05
通讯作者: 李萍；王华；马琳 E-mail:liping20081110@126.com; huawang@hospital.cqmu.edu.cn; bch_maleen@aliyun.com
基金资助:
北京市医院管理中心“登峰”人才培养计划（DFL20241201）

Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children（2026 edition）

Pediatric Dermatology Group, Chinese Society of Dermatology; Dermatology Group, Chinese Pediatric Society, Chinese Medical Association; Pediatric Group, Chinese Association of Rehabilitation Dermatology; Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology; Pediatric Dermatology Group, China Dermatologist Association; Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association

Pediatric Dermatology Group, Chinese Society of Dermatology; Dermatology Group, Chinese Pediatric Society, Chinese Medical Association; Pediatric Group, Chinese Association of Rehabilitation Dermatology; Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology; Pediatric Dermatology Group, China Dermatologist Association; Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association

Received:2025-08-27 Revised:2026-04-18 Published:2026-06-05
Contact: Li Ping; Wang Hua; Ma Lin E-mail:liping20081110@126.com; huawang@hospital.cqmu.edu.cn; bch_maleen@aliyun.com
Supported by:
Beijing Hospitals Authority′s Ascent Plan（DFL20241201）

摘要/Abstract

摘要： 【摘要】特应性皮炎（AD）是儿童常见的慢性、复发性、炎症性、瘙痒性皮肤病，不仅影响患儿的睡眠质量、生长发育、学习效率、社交能力及心理健康，还显著降低患儿及其家庭生活质量，增加医疗、社会及经济多维度疾病负担。近年来，AD发病机制的研究不断深入，表皮屏障功能障碍、2型免疫应答异常、微生态失衡及遗传易感性共同参与疾病发生发展。生物制剂及小分子靶向药物的问世，标志着AD治疗进入精准治疗时代，疾病管理理念亦由“症状控制”向“全周期管理与疾病修饰”转变。同时，AD的早期预测与预防策略取得进展，使得“早期预防、精准治疗及全程管理”成为有效防治的核心。本共识以“预测预防-阶梯治疗-共病管理-全程管理”为核心框架，重点阐述三级预防策略、分级与个体化治疗策略、常见并发症及共病的识别与处理，以及患者教育与长期全程管理等关键维度，旨在为我国儿童AD“预防-治疗-管理”三位一体的临床实践提供科学、规范且实用的参考依据，切实提升防治成效，改善患儿的长期预后，提高患儿及其家庭的生活质量，并有效减轻整体疾病负担。

关键词: 皮炎, 特应性, 儿童, 预防, 治疗, 管理, 共识

Abstract: 【Abstract】 Atopic dermatitis （AD） is a common chronic, recurrent, inflammatory, and pruritic skin disease in children. It not only affects sleep quality, growth and development, learning efficiency, social functioning, and mental health, but also significantly reduces the quality of life of affected children and their families, and increases multidimensional medical, social, and economic burdens. In recent years, research into the pathogenesis of AD has advanced substantially, demonstrating that epidermal barrier dysfunction, aberrant type 2 immune responses, microbial dysbiosis, and genetic susceptibility jointly contribute to disease onset and progression. The emergence of biologics and small-molecule targeted therapies has marked the entry of AD treatment into the era of precision medicine, while the concepts in disease management have shifted from “symptom control” to “whole-process management and disease modification”. Meanwhile, progress has been achieved in early prediction and prevention strategies for AD, and “early prevention, precision treatment, and whole-process management” are considered the core principles of effective disease control. This consensus adopts “prediction and prevention-stepwise treatment-comorbidity management-whole-process management” as its core framework, with a focus on key dimensions including tertiary prevention strategies, stratified and individualized treatment approaches, identification and management of common complications and comorbidities, as well as patient education and long-term management. It aims to provide a scientific, standardized, and practical reference for the integrated clinical practice of “prevention-treatment-management” for childhood AD in China, thereby improving prevention and treatment outcomes, enhancing long-term prognosis, improving the quality of life of affected children and their families, and effectively reducing the overall disease burden.

Key words: Dermatitis, atopic, Child, Prevention, Therapy, Management, Consensus

中华医学会皮肤性病学分会儿童皮肤病学组中华医学会儿科学分会皮肤病学组中国康复医学会皮肤病康复专业委员会儿童学组中国康复医学会皮肤病康复专业委员会特应性皮炎学组中国医师协会皮肤科医师分会儿童皮肤病学组中国医师协会儿科学分会皮肤病学组. [开放获取] 中国儿童特应性皮炎预防、治疗与管理实践共识（2026版）[J]. 中华皮肤科杂志, 2026,59(6):487-504. doi:10.35541/cjd.20250462

Pediatric Dermatology Group, Chinese Society of Dermatology, Dermatology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Group, Chinese Association of Rehabilitation Dermatology, Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association. Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children（2026 edition）[J]. Chinese Journal of Dermatology, 2026, 59(6): 487-504.doi:10.35541/cjd.20250462

参考文献 119

［1］	Ständer S. Atopic dermatitis［J］. N Engl J Med, 2021, 384（12）: 1136⁃1143. DOI: 10.1056/NEJMra2023911.
［2］	Kisieliene I, Mainelis A, Rudzeviciene O, et al. The burden of pediatric atopic dermatitis: quality of life of patients and their families［J］. J Clin Med, 2024,13（6）:1700. DOI: 10.3390/jcm 13061700.
［3］	Martin PE, Eckert JK, Koplin JJ, et al. Which infants with eczema are at risk of food allergy? Results from a population⁃based cohort［J］. Clin Exp Allergy, 2015,45（1）:255⁃264. DOI: 10.1111/cea.12406.
［4］	Chiesa Fuxench ZC, Mitra N, Del Pozo D, et al. Risk of atopic dermatitis and the atopic march paradigm in children of mothers with atopic illnesses: a birth cohort study from the United Kingdom［J］. J Am Acad Dermatol, 2024,90（3）:561⁃568. DOI: 10.1016/j.jaad.2023.11.013.
［5］	Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis［J］. J Am Acad Dermatol, 2014,70（2）:338⁃351. DOI: 10.1016/j.jaad.2013.10.010.
［6］	Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases［J］. N Engl J Med, 2011,365（14）:1315⁃1327. DOI: 10.1056/NEJMra1011040.
［7］	Margolis DJ. Atopic dermatitis: filaggrin and skin barrier dysfunction［J］. Br J Dermatol, 2022,186（3）:396. DOI: 10.1111/bjd.20946.
［8］	Egawa G, Kabashima K. Barrier dysfunction in the skin allergy［J］. Allergol Int, 2018,67（1）:3⁃11. DOI: 10.1016/j.alit.2017. 10.002.
［9］	van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta⁃analysis［J］. BMJ, 2009,339:b2433. DOI: 10.1136/bmj.b2433.
［10］	Horimukai K, Morita K, Narita M, et al. Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations［J］. Allergol Int, 2016,65（1）:103⁃108. DOI: 10.1016/j.alit.2015. 09.004.
［11］	Berdyshev E, Kim J, Kim BE, et al. Stratum corneum lipid and cytokine biomarkers at age 2 months predict the future onset of atopic dermatitis［J］. J Allergy Clin Immunol, 2023,151（5）:1307⁃1316. DOI: 10.1016/j.jaci.2023.02.013.
［12］	Rinnov MR, Halling AS, Gerner T, et al. Skin biomarkers predict development of atopic dermatitis in infancy［J］. Allergy, 2023,78（3）:791⁃802. DOI: 10.1111/all.15518.
［13］	Yamamoto⁃Hanada K, Saito⁃Abe M, Shima K, et al. mRNAs in skin surface lipids unveiled atopic dermatitis at 1 month［J］. J Eur Acad Dermatol Venereol, 2023,37（7）:1385⁃1395. DOI: 10.1111/jdv.19017.
［14］	Miyahara H, Okazaki N, Nagakura T, et al. Elevated umbilical cord serum TARC/CCL17 levels predict the development of atopic dermatitis in infancy［J］. Clin Exp Allergy, 2011,41（2）:186⁃191. DOI: 10.1111/j.1365⁃2222.2010.03634.x.
［15］	Meylan P, Lang C, Mermoud S, et al. Skin colonization by Staphylococcus aureus precedes the clinical diagnosis of atopic dermatitis in infancy［J］. J Invest Dermatol, 2017,137（12）:2497⁃2504. DOI: 10.1016/j.jid.2017.07.834.
［16］	Halling AS, Fritz BG, Gerner T, et al. Reduced skin microbiome diversity in infancy is associated with increased risk of atopic dermatitis in high⁃risk children［J］. J Invest Dermatol, 2023,143（10）:2030⁃2038. DOI: 10.1016/j.jid.2023.03.1682.
［17］	Kennedy EA, Connolly J, Hourihane JO, et al. Skin microbiome before development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year［J］. J Allergy Clin Immunol, 2017,139（1）:166⁃172. DOI: 10.1016/j.jaci.2016.07.029.
［18］	Zhao M, Li X, Li Y, et al. Multi⁃omics profiling of the 42⁃day infant gut as a pilot predictor of atopic dermatitis at one year: a birth cohort study in China［J］. J Inflamm Res, 2025,18:11205⁃11216. DOI: 10.2147/JIR.S534551.
［19］	Williams HC, Chalmers J. Prevention of atopic dermatitis［J］. Acta Derm Venereol, 2020,100（12）:adv00166. DOI: 10.2340/00015555⁃3516.
［20］	Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond［J］. Br J Dermatol, 2019,180（3）:464⁃474. DOI: 10.1111/bjd.16934.
［21］	Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention［J］. J Allergy Clin Immunol, 2014,134（4）:818⁃823. DOI: 10.1016/j.jaci.2014.08.005.
［22］	Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis［J］. J Allergy Clin Immunol, 2014,134（4）:824⁃830. DOI: 10.1016/j.jaci.2014.07.060.
［23］	Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial［J］. Lancet, 2020,395（10228）:962⁃972. DOI: 10.1016/S0140⁃6736（19）32984⁃8.
［24］	Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis （PreventADALL）: a factorial, multicentre, cluster⁃randomised trial［J］. Lancet, 2020,395（10228）:951⁃961. DOI: 10.1016/S0140⁃6736（19）32983⁃6.
［25］	Liang J, Hu F, Tang H, et al. Systematic review and network meta⁃analysis of different types of emollient for the prevention of atopic dermatitis in infants［J］. J Eur Acad Dermatol Venereol, 2023,37（3）:501⁃510. DOI: 10.1111/jdv.18688.
［26］	Ní Chaoimh C, Lad D, Nico C, et al. Early initiation of short⁃term emollient use for the prevention of atopic dermatitis in high⁃risk infants⁃The STOP⁃AD randomised controlled trial［J］. Allergy, 2023,78（4）:984⁃994. DOI: 10.1111/all.15491.
［27］	Simpson EL, Michaels LC, Ramsey K, et al. Emollients to prevent pediatric eczema: a randomized clinical trial［J］. JAMA Dermatol, 2025,161（9）:957⁃965. DOI: 10.1001/jamadermatol. 2025.2357.
［28］	Werfel T, Heratizadeh A, Aberer W, et al. S3 Guideline atopic dermatitis: part 1 ⁃ general aspects, topical and non⁃drug therapies, special patient groups［J］. J Dtsch Dermatol Ges, 2024,22（1）:137⁃153. DOI: 10.1111/ddg.15230.
［29］	Wang F, Wu F, Chen H, et al. The effect of probiotics in the prevention of atopic dermatitis in children: a systematic review and meta⁃analysis［J］. Transl Pediatr, 2023,12（4）:731⁃748. DOI: 10.21037/tp⁃23⁃200.
［30］	Tan⁃Lim C, Esteban⁃Ipac N, Recto M, et al. Comparative effectiveness of probiotic strains on the prevention of pediatric atopic dermatitis: a systematic review and network meta⁃analysis［J］. Pediatr Allergy Immunol, 2021,32（6）:1255⁃1270. DOI: 10.1111/pai.13514.
［31］	Miller JD. The role of dust mites in allergy［J］. Clin Rev Allergy Immunol, 2019,57（3）:312⁃329. DOI: 10.1007/s12016⁃018⁃8693⁃0.
［32］	Bremmer SF, Simpson EL. Dust mite avoidance for the primary prevention of atopic dermatitis: a systematic review and meta⁃analysis［J］. Pediatr Allergy Immunol, 2015,26（7）:646⁃654. DOI: 10.1111/pai.12452.
［33］	Wang J, Janson C, Malinovschi A, et al. Asthma, allergic rhinitis and atopic dermatitis in association with home environment ⁃ the RHINE study［J］. Sci Total Environ, 2022,853:158609. DOI: 10.1016/j.scitotenv.2022.158609.
［34］	Jabbar⁃Lopez ZK, Ung CY, Alexander H, et al. The effect of water hardness on atopic eczema, skin barrier function: a systematic review, meta⁃analysis［J］. Clin Exp Allergy, 2021,51（3）:430⁃451. DOI: 10.1111/cea.13797.
［35］	Ai S, Liu L, Xue Y, et al. Prenatal exposure to air pollutants associated with allergic diseases in children: which pollutant, when exposure, and what disease? A systematic review and meta⁃analysis［J］. Clin Rev Allergy Immunol, 2024,66（2）:149⁃163. DOI: 10.1007/s12016⁃024⁃08987⁃3.
［36］	Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party′s Diagnostic Criteria for Atopic Dermatitis.Ⅰ. Derivation of a minimum set of discriminators for atopic dermatitis［J］. Br J Dermatol, 1994,131（3）:383⁃396. DOI: 10.1111/j.1365⁃2133. 1994.tb08530.x.
［37］	Cheng R, Zhang H, Zong W, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:542⁃548. DOI: 10.1111/jdv.15979.
［38］	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. DOI: 10.35541/cjd.20191000.
［39］	中华医学会, 中华医学会杂志社, 中华医学会皮肤性病学分会, 等. 儿童特应性皮炎基层诊疗指南（2023年）［J］. 中华全科医师杂志, 2023,22（1）:8⁃18. DOI: 10.3760/cma.j.cn114798⁃20220915⁃00924.
［40］	Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema ⁃ part Ⅱ: non⁃systemic treatments and treatment recommendations for special AE patient populations［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1904⁃1926. DOI: 10.1111/jdv.18429.
［41］	Obbagy JE, English LK, Wong YP, et al. Complementary feeding and food allergy, atopic dermatitis/eczema, asthma, and allergic rhinitis: a systematic review［J］. Am J Clin Nutr, 2019,109（Suppl_7）:890S⁃934S. DOI: 10.1093/ajcn/nqy220.
［42］	Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermatitis cause food allergy? A systematic review［J］. J Allergy Clin Immunol, 2016,137（4）:1071⁃1078. DOI: 10.1016/j.jaci.2015. 10.049.
［43］	中国医师协会皮肤科医师分会儿童皮肤病专业委员会, 中华医学会皮肤性病学分会儿童学组, 中华医学会儿科学分会皮肤性病学组. 儿童特应性皮炎相关食物过敏诊断与管理专家共识［J］. 中华皮肤科杂志, 2019,52（10）:711⁃716. DOI: 10. 35541/cjd.20190586.
［44］	Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta⁃analysis of the dupilumab atopic dermatitis database for incident allergic events［J］. J Allergy Clin Immunol, 2023,151（3）:756⁃766. DOI: 10.1016/j.jaci.2022.08.026.
［45］	Lin TL, Fan YH, Fan KS, et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: a population⁃based cohort study［J］. J Am Acad Dermatol, 2024,91（3）:466⁃473. DOI: 10.1016/j.jaad.2024.05.029.
［46］	Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis［J］. Br J Dermatol, 2014,170（Suppl 1）:38⁃43. DOI: 10.1111/bjd.13084.
［47］	Silverberg JI, Gooderham M, Katoh N, et al. Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus⁃based recommendations for systemic therapy［J］. Br J Dermatol, 2023,188（Supplement_2）:ljac140.022. DOI: 10.1093/bjd/ljac140.022.
［48］	王珊, 何黎, 王华, 等. 功效性护肤品在儿童特应性皮炎中的应用指南［J］. 中国皮肤性病学杂志, 2020,34（9）:977⁃981. DOI: 10.13735/j.cjdv.1001⁃7089.202006019.
［49］	Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017［J］. Allergol Int, 2017,66（2）:230⁃247. DOI: 10.1016/j.alit.2016.12.003.
［50］	Eichenfield LF, Boguniewicz M, Simpson EL, et al. Translating atopic dermatitis management guidelines into practice for primary care providers［J］. Pediatrics, 2015,136（3）:554⁃565. DOI: 10.1542/peds.2014⁃3678.
［51］	Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group［J］. Br J Dermatol, 1999,140（6）:1114⁃1121. DOI: 10.1046/j.1365⁃2133.1999.02893.x.
［52］	Lax SJ, Harvey J, Axon E, et al. Strategies for using topical corticosteroids in children and adults with eczema［J］. Cochrane Database Syst Rev, 2022,3:CD013356. DOI: 10.1002/14651858.CD013356.pub2.
［53］	Lax SJ, Van Vogt E, Candy B, et al. Topical anti⁃inflammatory treatments for eczema: network meta⁃analysis［J］. Cochrane Database Syst Rev, 2024,8:CD015064. DOI: 10.1002/14651858.CD015064.pub2.
［54］	Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5⁃year randomized trial［J］. Pediatrics, 2015,135（4）:597⁃606. DOI: 10.1542/peds.2014⁃1990.
［55］	梁源, 刘玲玲, 王珊, 等. 0.03％他克莫司软膏长期间歇维持治疗儿童特应性皮炎的多中心随机对照临床研究［J］. 中华皮肤科杂志, 2019,52（8）:519⁃524. DOI: 10.3760/cma.j.issn. 0412⁃4030.2019.08.001.
［56］	Saeki H, Ohya Y, Arakawa H, et al. Executive summary: Japanese guidelines for atopic dermatitis （ADGL） 2024［J］. Allergol Int, 2025,74（2）:210⁃221. DOI: 10.1016/j.alit.2025. 01.003.
［57］	Luger T, Augustin M, Lambert J, et al. Unmet medical needs in the treatment of atopic dermatitis in infants: an expert consensus on safety and efficacy of pimecrolimus［J］. Pediatr Allergy Immunol, 2021,32（3）:414⁃424. DOI: 10.1111/pai.13422.
［58］	Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years［J］. Pediatrics, 2006,117（1）:e118⁃e128. DOI: 10.1542/peds.2005⁃1188.
［59］	Eichenfield LF, Call RS, Forsha DW, et al. Long⁃term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis［J］. J Am Acad Dermatol, 2017,77（4）:641⁃649. DOI: 10.1016/j.jaad.2017.06.010.
［60］	Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild⁃to⁃moderate atopic dermatitis: a phase Ⅳ open⁃label study （CrisADe CARE 1）［J］. Am J Clin Dermatol, 2020,21（2）:275⁃284. DOI: 10.1007/s40257⁃020⁃00510⁃6.
［61］	Yang H, Li P, Shu H, et al. Efficacy and safety of proactive therapy with 2% crisaborole ointment in children with mild⁃to⁃moderate atopic dermatitis: a randomized controlled study［J］. Paediatr Drugs, 2025,27（3）:367⁃376. DOI: 10.1007/s40272⁃025⁃00682⁃w.
［62］	王珊, 王星宇, 舒虹, 等. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究［J］. 中华皮肤科杂志, 2023,56（9）:815⁃821. DOI: 10.35541/cjd.20230255.
［63］	Polonio CM, McHale KA, Sherr DH, et al. The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation［J］. Nat Rev Drug Discov, 2025,24（8）:610⁃630. DOI: 10.1038/s41573⁃025⁃01172⁃x.
［64］	Trujillo⁃Ochoa JL, Kazemian M, Afzali B. The role of transcription factors in shaping regulatory T cell identity［J］. Nat Rev Immunol, 2023,23（12）:842⁃856. DOI: 10.1038/s41577⁃023⁃00893⁃7.
［65］	Xiong L, Dean JW, Fu Z, et al. Ahr⁃Foxp3⁃RORγt axis controls gut homing of CD4+ T cells by regulating GPR15［J］. Sci Immunol, 2020,5（48）:eaaz7277. DOI: 10.1126/sciimmunol.aaz7277.
［66］	Quintana FJ, Basso AS, Iglesias AH, et al. Control of Treg and Th17 cell differentiation by the aryl hydrocarbon receptor［J］. Nature, 2008,453（7191）:65⁃71. DOI: 10.1038/nature06880.
［67］	Gagliani N, Amezcua Vesely MC, Iseppon A, et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation［J］. Nature, 2015,523（7559）:221⁃225. DOI: 10. 1038/nature14452.
［68］	Furue M, Tsuji G, Mitoma C, et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor［J］. J Dermatol Sci, 2015,80（2）:83⁃88. DOI: 10.1016/j.jdermsci. 2015.07.011.
［69］	Chen Z, Dragan M, Sun P, et al. The AhR⁃Ovol1⁃Id1 regulatory axis in keratinocytes promotes epidermal and immune homeostasis in atopic dermatitis⁃like skin inflammation［J］. Cell Mol Immunol, 2025,22（3）:300⁃315. DOI: 10.1038/s41423⁃025⁃01264⁃z.
［70］	Smits J, Ederveen T, Rikken G, et al. Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR⁃dependent induction of antimicrobial peptides［J］. J Invest Dermatol, 2020,140（2）:415⁃424. DOI: 10.1016/j.jid.2019.06.142.
［71］	Edamitsu T, Taguchi K, Okuyama R, et al. AHR and NRF2 in skin homeostasis and atopic dermatitis［J］. Antioxidants （Basel）, 2022,11（2）:227. DOI: 10.3390/antiox11020227.
［72］	Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double⁃blind studies［J］. J Am Acad Dermatol, 2021,85（4）:863⁃872. DOI: 10.1016/j.jaad.2021. 04.085.
［73］	Nakagawa H, Igarashi A, Saeki H, et al. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: a phase 3, open⁃label, and long⁃term study［J］. Allergol Int, 2024,73（1）:137⁃142. DOI: 10.1016/j.alit.2023.04. 003.
［74］	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组. 特应性皮炎湿包疗法临床应用专家共识［J］. 中华皮肤科杂志, 2022,55（4）:289⁃294. DOI: 10.35541/cjd.20210823.
［75］	Nicol NH, Boguniewicz M. Wet wrap therapy in moderate to severe atopic dermatitis［J］. Immunol Allergy Clin North Am, 2017,37（1）:123⁃139. DOI: 10.1016/j.iac.2016.08.003.
［76］	中华医学会皮肤性病学分会免疫学组, 中国研究型医院学会皮肤科学专业委员会. 中重度特应性皮炎分层个体化系统治疗专家共识［J］. 中华皮肤科杂志, 2024,57（12）:1071⁃1078. DOI: 10.35541/cjd.20240321.
［77］	Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double⁃blinded, placebo⁃controlled phase 3 trial［J］. J Am Acad Dermatol, 2020,83（5）:1282⁃1293. DOI: 10.1016/j.jaad.2020. 06.054.
［78］	Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs［J］. Allergy, 2024,79（6）:1501⁃1515. DOI: 10.1111/all.16009.
［79］	Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate⁃to⁃severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase Ⅲ, randomized, double⁃blind, placebo⁃controlled study （BREEZE⁃AD PEDS）［J］. Br J Dermatol, 2023,189（1）:23⁃32. DOI: 10.1093/bjd/ljad096.
［80］	Guttman⁃Yassky E, Teixeira HD, Simpson EL, et al. Once⁃daily upadacitinib versus placebo in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （Measure Up 1 and Measure Up 2）: results from two replicate double⁃blind, randomised controlled phase 3 trials［J］. Lancet, 2021,397（10290）:2151⁃2168. DOI: 10.1016/S0140⁃6736（21）00588⁃2.
［81］	Li L, Yu J, Chen B, et al. Efficacy and safety of abrocitinib for moderate⁃to⁃severe atopic dermatitis in adolescents and adults: meta⁃analysis［J］. Front Pharmacol, 2023,14:1154949. DOI: 10.3389/fphar.2023.1154949.
［82］	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中国老年保健医学研究会皮肤科分会. 系统Janus激酶抑制剂治疗特应性皮炎专家共识［J］. 实用皮肤病学杂志, 2022,15（3）:129⁃135. DOI: 10.11786/sypfbxzz.1674⁃1293. 20220301.
［83］	Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part Ⅱ［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:850⁃878. DOI: 10.1111/jdv. 14888.
［84］	Mancuso JB, Lee SS, Paller AS, et al. Management of severe atopic dermatitis in pediatric patients［J］. J Allergy Clin Immunol Pract, 2021,9（4）:1462⁃1471. DOI: 10.1016/j.jaip.2021. 02.017.
［85］	Davis D, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies［J］. J Am Acad Dermatol, 2024,90（2）:e43⁃e56. DOI: 10.1016/j.jaad.2023.08.102.
［86］	LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis［J］. Pediatr Dermatol, 2019,36（1）:36⁃65. DOI: 10.1111/pde.13678.
［87］	Sawangjit R, Dilokthornsakul P, Lloyd⁃Lavery A, et al. Systemic treatments for eczema: a network meta⁃analysis［J］. Cochrane Database Syst Rev, 2020,9:CD013206. DOI: 10.1002/14651858.CD013206.pub2.
［88］	Seccombe E, Wynne MD, Clancy C, et al. A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit［J］. Photodermatol Photoimmunol Photomed, 2021,37（1）:34⁃38. DOI: 10.1111/phpp.12604.
［89］	中国研究型医院学会皮肤科学专业委员会, 中国医师协会皮肤科医师分会. 长波紫外线1皮肤科临床应用专家共识（2022）［J］. 中华皮肤科杂志, 2022,55（11）:956⁃961. DOI: 10.35541/cjd.20220423.
［90］	中国医师协会皮肤科医师分会规范化诊疗工作委员会, 中国医学装备协会皮肤病与皮肤美容专业委员会皮肤外科装备学组和皮肤光治疗学组. 窄谱中波紫外线家庭光疗临床应用专家共识［J］. 中华皮肤科杂志, 2019,52（3）:156⁃161. DOI: 10.3760/cma.j.issn.0412⁃4030.2019.03.002.
［91］	万朋杰, 杨绍芳, 齐珺. 局部窄谱中波紫外线联合地奈德乳膏治疗儿童中重度特应性皮炎的疗效观察［J］. 上海交通大学学报（医学版）, 2026,46（1）:132⁃136. DOI: 10.3969/j.issn.1674⁃8115.2026.01.016.
［92］	AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis （eczema） guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE⁃ and Institute of Medicine⁃based recommendations［J］. Ann Allergy Asthma Immunol, 2024,132（3）:274⁃312. DOI: 10.1016/j.anai.2023.11. 009.
［93］	Yepes⁃Nuñez JJ, Guyatt GH, Gómez⁃Escobar LG, et al. Allergen immunotherapy for atopic dermatitis: systematic review and meta⁃analysis of benefits and harms［J］. J Allergy Clin Immunol, 2023,151（1）:147⁃158. DOI: 10.1016/j.jaci.2022.09.020.
［94］	中国医药教育协会儿科专业委员会, 中华医学会儿科学分会呼吸学组哮喘协作组, 福棠儿童医学发展研究中心过敏（变态）反应学科规范化建设研究组, 等. 儿童过敏性哮喘尘螨过敏原特异性免疫治疗循证指南（医生版）［J］. 中华实用儿科临床杂志, 2024,39（6）:401⁃417. DOI: 10.3760/cma.j.cn101070⁃20240223⁃00106.
［95］	Raffi J, Suresh R, Botto N, et al. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review［J］. J Am Acad Dermatol, 2020,82（1）:132⁃138. DOI: 10.1016/j.jaad.2019.09.028.
［96］	Fonacier LS, Aquino MR. The role of contact allergy in atopic dermatitis［J］. Immunol Allergy Clin North Am, 2010,30（3）:337⁃350. DOI: 10.1016/j.iac.2010.06.001.
［97］	Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis （ADGL） 2021［J］. Allergol Int, 2022,71（4）:448⁃458. DOI: 10.1016/j.alit.2022.06.009.
［98］	Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders［J］. Am J Clin Dermatol, 2018,19（6）:821⁃838. DOI: 10.1007/s40257⁃018⁃0383⁃4.
［99］	Johnson H, Aquino MR, Snyder A, et al. Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: a multicenter retrospective case⁃control study［J］. J Am Acad Dermatol, 2023,89（5）:1007⁃1014. DOI: 10.1016/j.jaad.2023.06. 048.
［100］	中国医师协会皮肤科医师分会过敏性疾病专业委员会. 斑贴试验临床应用专家共识（2020修订版）［J］. 中华皮肤科杂志, 2020,53（4）:239⁃243. DOI: 10.35541/cjd.20190873.
［101］	Papapostolou N, Xepapadaki P, Gregoriou S, et al. Atopic dermatitis and food allergy: a complex interplay what we know and what we would like to learn［J］. J Clin Med, 2022,11（14）:4232. DOI: 10.3390/jcm11144232.
［102］	Sampson HA. Food allergy. Part 1: immunopathogenesis and clinical disorders［J］. J Allergy Clin Immunol, 1999,103（5 Pt 1）:717⁃728. DOI: 10.1016/s0091⁃6749（99）70411⁃2.
［103］	Burks AW, James JM, Hiegel A, et al. Atopic dermatitis and food hypersensitivity reactions［J］. J Pediatr, 1998,132（1）:132⁃136. DOI: 10.1016/s0022⁃3476（98）70498⁃6.
［104］	Greenhawt M. The role of food allergy in atopic dermatitis［J］. Allergy Asthma Proc, 2010,31（5）:392⁃397. DOI: 10.2500/aap.2010.31.3393.
［105］	Peters RL, Krawiec M, Koplin JJ, et al. Update on food allergy［J］. Pediatr Allergy Immunol, 2021,32（4）:647⁃657. DOI: 10. 1111/pai.13443.
［106］	Saeki H, Ohya Y, Furuta J, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2021［J］. J Dermatol, 2022,49（10）:e315⁃e375. DOI: 10.1111/1346⁃8138.16527.
［107］	中国医师协会变态反应医师分会, 福棠儿童医学发展研究中心, 北京医师协会变态反应专科医师分会. 过敏原特异性IgE检测结果临床解读中国专家共识［J］. 中华预防医学杂志, 2022,56（6）:707⁃725. DOI: 10.3760/cma.j.cn112150⁃2022 0320⁃00263.
［108］	Eigenmann PA, Atanaskovic⁃Markovic M, O′B Hourihane J, et al. Testing children for allergies: why, how, who and when: an updated statement of the European Academy of Allergy and Clinical Immunology （EAACI） Section on Pediatrics and the EAACI⁃Clemens von Pirquet Foundation［J］. Pediatr Allergy Immunol, 2013,24（2）:195⁃209. DOI: 10.1111/pai.12066.
［109］	Ćosićkić A, Skokić F, Selimović A, et al. Development of respiratory allergies, asthma and allergic rhinitis in children with atopic dermatitis［J］. Acta Clin Croat, 2017,56（2）:308⁃317. DOI: 10.20471/acc.2017.56.02.15.
［110］	Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis［J］. Int Forum Allergy Rhinol, 2018,8（2）:108⁃352. DOI: 10.1002/alr. 22073.
［111］	Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes［J］. Am J Respir Crit Care Med, 2022,205（1）:17⁃35. DOI: 10.1164/rccm.202109⁃2205PP.
［112］	Govind K, Whang K, Khanna R, et al. Atopic dermatitis is associated with increased prevalence of multiple ocular comorbidities［J］. J Allergy Clin Immunol Pract, 2019,7（1）:298⁃299. DOI: 10.1016/j.jaip.2018.10.009.
［113］	Huang AH, Roh YS, Sutaria N, et al. Real⁃world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States［J］. J Am Acad Dermatol, 2021,85（4）:893⁃900. DOI: 10.1016/j.jaad.2021.03.016.
［114］	Kern C, Wan J, LeWinn KZ, et al. Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study［J］. JAMA Dermatol, 2021,157（10）:1200⁃1208. DOI: 10.1001/jamadermatol.2021.2657.
［115］	Moore K, David TJ, Murray CS, et al. Effect of childhood eczema and asthma on parental sleep and well⁃being: a prospective comparative study［J］. Br J Dermatol, 2006,154（3）:514⁃518. DOI: 10.1111/j.1365⁃2133.2005.07082.x.
［116］	Fessler MB, Jaramillo R, Crockett PW, et al. Relationship of serum cholesterol levels to atopy in the US population［J］. Allergy, 2010,65（7）:859⁃864. DOI: 10.1111/j.1398⁃9995. 2009.02287.x.
［117］	Silverberg JI, Becker L, Kwasny M, et al. Central obesity and high blood pressure in pediatric patients with atopic dermatitis［J］. JAMA Dermatol, 2015,151（2）:144⁃152. DOI: 10.1001/jamadermatol.2014.3059.
［118］	Andrade LF, Abdi P, Mashoudy KD, et al. Effectiveness of atopic dermatitis patient education programs ⁃ a systematic review and meta⁃analysis［J］. Arch Dermatol Res, 2024,316（5）:135. DOI: 10.1007/s00403⁃024⁃02871⁃y.
［119］	中华医学会皮肤性病学分会儿童学组, 中华医学会儿科学分会皮肤性病学组, 中国康复医学会皮肤病康复专业委员会, 等. 中国儿童特应性皮炎专病门诊建设及标准化病案管理专家共识（2025版）［J/OL］. 中华皮肤科杂志, 2025,e20240338（2025⁃03⁃12）［2025⁃12⁃08］. http：//www.pifukezazhi.com/CN/10.35541/cjd.20240338.［网络预发表］.

[1]	田静宋志强. 胶带剥离法在特应性皮炎生物标志物检测中的研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 578-581.
[2]	李明李妍李邻峰. Janus激酶抑制剂在中重度特应性皮炎中的应用进展[J]. 中华皮肤科杂志, 2026, 59(6): 582-585.
[3]	李芳林颖. 头颈部特应性皮炎的诊疗研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 586-590.
[4]	马铜川邓婷月肖风丽. 吸烟与特应性皮炎相关性研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 590-593.
[5]	孙松朋龙俊红褚洪川周阳洋刘甲鑫刘彦霍兴霄陈航荆涛高静王艳逊王锐李振宇张书信. 肤痔清软膏与曲安奈德益康唑乳膏治疗肛周慢性湿疹的临床疗效和安全性：一项多中心、随机、对照、双盲、等效性研究[J]. 中华皮肤科杂志, 2026, 59(6): 564-570.
[6]	杜欣冉王歆荷李思宇陈谟安袁少杰鄢然程淋燕郭婉军王怡李福伦. [开放获取] 特应性皮炎血虚风燥证诊断量表的构建及评价研究[J]. 中华皮肤科杂志, 2026, 59(6): 540-546.
[7]	许朋高玉文卢梦梁雄顺李雁冰洪文旭赵志广关杨. 槲皮素对DNFB诱导的特应性皮炎样小鼠肠道菌群稳态及炎症因子的影响及其与症状改善的关联分析[J]. 中华皮肤科杂志, 2026, 59(6): 529-539.
[8]	秦琬宜路永红唐欣韵周思婕周培媚. [开放获取] 度普利尤单抗/Janus激酶1抑制剂治疗中重度特应性皮炎的1年药物留存分析[J]. 中华皮肤科杂志, 2026, 59(6): 512-518.
[9]	张汉伊郭也也肖易陈翔粟娟. 慢性心理应激介导脂质代谢与免疫微环境异常在特应性皮炎样小鼠中的作用[J]. 中华皮肤科杂志, 2026, 59(6): 519-528.
[10]	伍博陈星柴圆圆曹蓉陈钱朱红艳. 不同严重程度儿童特应性皮炎血清维生素D水平与巨噬细胞炎症的相关性分析[J]. 中华皮肤科杂志, 2026, 59(6): 547-552.
[11]	李雁冰许朋田佳彬林秀球刘慧赵志广李祥子关杨. 成人特应性皮炎流行病学分析：基于2023年深圳市慢性病及危险因素监测数据[J]. 中华皮肤科杂志, 2026, 59(6): 553-557.
[12]	葛佳艺刘伊瑄周园姚煦. 特应性皮炎中移动健康与数字生物标志物的研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 571-577.
[13]	李巍姚煦. 中国特应性皮炎的研究现状与展望[J]. 中华皮肤科杂志, 2026, 59(6): 505-511.
[14]	中国“一带一路”皮肤病学专科联盟水疱病专病联盟中华医学会皮肤性病学分会天疱疮/大疱性类天疱疮研究协作组. 抗p200类天疱疮诊断与治疗专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 387-395.
[15]	中国妇幼保健协会儿童变态反应专业委员会儿童皮肤病学组. 儿童肛门生殖器硬化性苔藓诊疗管理中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 396-406.

[开放获取] 中国儿童特应性皮炎预防、治疗与管理实践共识（2026版）

Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children（2026 edition）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 119

相关文章 15

Metrics

本文评价

推荐阅读 10